# Federal Register #DEA-1568M

DEA adjusts 2026 production quotas for four Schedule II controlled substances

**Buyer:** Justice Department / Drug Enforcement Administration
**Posted:** November 10, 2026
**Identifier:** DEA-1568M

The Drug Enforcement Administration adjusted 2026 production quotas for four Schedule II controlled substances; this is a regulatory action, not a purchase or contract award.
- **Government buyer:** U.S. Department of Justice, Drug Enforcement Administration (DEA); no specific office is identified.
- **Quota adjustments:**
  - d,l-amphetamine: 31,654,915 grams, increased from 24,234,443 grams.
  - d-amphetamine (for sale): 37,108,041 grams, increased from 26,450,000 grams.
  - Hydromorphone: 2,356,798 grams, increased from 1,949,378 grams.
  - Methylphenidate (for sale): 69,502,651 grams, increased from 58,283,000 grams.
- The quotas are stated in grams of anhydrous acid or base and are intended to support medical needs, exports, and reserve stocks.
- **OEMs and vendors:** None identified. No products are being solicited for purchase.

### Description

The Drug Enforcement Administration is adjusting the 2026 aggregate production quotas for d,l-amphetamine, d-amphetamine (for sale), hydromorphone, and methylphenidate (for sale). The adjustments increase the quotas to support estimated domestic medical needs, export requirements, and reserve stocks. DEA states that it considered the applicable statutory and regulatory factors and issued the final order effective immediately on November 10, 2026.

[View original listing](https://www.federalregister.gov/documents/2026/11/10/2026-22842/adjustment-to-the-2026-aggregate-production-quota-for-dl-amphetamine-d-amphetamine-for-sale)